DAY 1

Welcome Note – Jaap Verweij (CDDF Board, NL)

TOPIC 1: THE RELEVANCE OF INDIVIDUAL COMPONENTS IN COMBINATION THERAPIES

Pharmacological & Clinical Trial Design Aspects – Ruth Plummer (Newcastle University, UK)

Pharma-Industry Perspective – Stefan Schwoch (Lilly, UK)

Regulatory Aspects and Guidances – Jorge Camarero (Spanish Agency of Medicines and Medical Devices, ES)

Novel Preclinical Models to Assess the Value of New Drug Combinations – James Doroshow (National Cancer Institute, US)

 

TOPIC 2: REFLECTIONS ON CDDF WORKSHOPS OF THE LAST 18 MONTHS

Biomarkers and Patient´s Access to Personalized Oncology Drugs in Europe –  Annie Pannelay (Romanian Health Observatory, UK)

Minimal Residual Disease (AML/CLL) – Irmela Radtke (Roche, CH)

Involving Patients in Oncology Drug Development – Claudia Hey (Merck Healthcare KGaA, DE)

The Use of Real-World Data to Optimize Oncology Drug Development and Access – Axel Glasmacher (CDDF, DE)